NCT05144178 (EHS-Strategy) is a clinical trial in COVID-19 Respiratory Infection, sponsored by Emirates Health Services (EHS).

Who is sponsoring NCT05144178?

NCT05144178 is sponsored by Emirates Health Services (EHS).

What condition does NCT05144178 study?

NCT05144178 studies COVID-19 Respiratory Infection.

Is NCT05144178 still recruiting?

NCT05144178 is currently status unknown. Last updated 3 January 2022.

Last reviewed 2022-01-03 · How we verify

NCT05144178: EHS-Strategy

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab )

Status unknown Last updated 3 January 2022

What this trial tests

trial in COVID-19 Respiratory Infection in 3,500 participants. Status unknown.

Timeline

14 November 2021

Primary endpoint
30 January 2022

9 February 2022

Quick facts

Lead sponsor	Emirates Health Services (EHS)
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	3,500
Start date	14 November 2021
Primary completion	30 January 2022
Estimated completion	9 February 2022
Sites	1 location across United Arab Emirates

Conditions studied

COVID-19 Respiratory Infection — all drugs for COVID-19 Respiratory Infection →

Sponsor

Emirates Health Services (EHS) — full company profile →

Who can join

13 and older, any sex, with COVID-19 Respiratory Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Sotrovimab is a newly developed monoclonal antibody for the treatment of mild and moderate COVID-19 patient, who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions. The safety and effectiveness of this investigational therapy continues to be evaluated for treatment of COVID-19. Sotrovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. As the clinical trial results are too preliminary for the drug to enter routine use in UAE the drug approved only for emergency use, until further evidence shows Sotrovimab is effective, so we thought about this study as a tool to assess the success of Emirats Health service (EHS) strategy for fighting against COVID-19 outside the hospital setting.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Sotrovimab: First Approval.
Heo YA. · · 2022 · cited 37× · PMID 35286623 · DOI 10.1007/s40265-022-01690-7
Keeping up with the COVID's-Could siRNA-based antivirals be a part of the answer?
Forgham H, Kakinen A, Qiao R, Davis TP. · · 2022 · cited 16× · PMID 35941991 · DOI 10.1002/exp.20220012
Use of Sotrovimab in 14 Children with COVID-19: A Single-center Experience.
Butzer SK, Habbig S, Mehler K, Haumann S, et al · · 2023 · cited 3× · PMID 36730080 · DOI 10.1097/inf.0000000000003781

Verify or expand the search:

Other recruiting trials for COVID-19 Respiratory Infection

Currently open trials in the same condition.

NCT06950177 — Pancoronavirus Vaccine Study in Healthy Adults · Phase 1 · active not recruiting
NCT06402318 — Passive Detection- SARS-CoV-2 (COVID-19) A&M Breathalyzer (PROTECT Kiosk) for Operational Medicine · recruiting
NCT05765396 — SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies · active not recruiting
NCT05689034 — Multicenter Randomized Double-blind Placebo-controlled Study to Investigate Azvudine in Symptomatic Adults With COVID-19 · Phase 2, PHASE3 · recruiting
NCT05562505 — Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure · NA · recruiting

Other Emirates Health Services (EHS) trials

Trials by the same sponsor.

NCT07395583 — Preventing Non-Contact Hamstring Injuries in Elite Footballers: Eccentric vs Concentric Training · NA · active not recruiting
NCT07115316 — EFFECTIVENESS OF ECCENTRIC HAMSTRING CONTRACTIONS WITH PHYSIOTHERAPY TRAINING ON SPORTS PERFORMANCE AND QUALITY OF LIFE · NA · recruiting
NCT05705388 — POSE2.0 With GLP-1 Agonist for Obesity Management · NA · unknown
NCT06135948 — Impact of Increasing Levothyroxine Dose in Ramadan for UAE Patients With Hypothyroidism · Phase 4 · completed
NCT05611567 — Endoscopic Gastric Plication Using the POSE2.0 Technique for Management of Fatty Liver Disease · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05144178 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emirates Health Services (EHS)
Last refreshed: 3 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05144178.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing